Research Article

Hemp from Past to Present

History, the Endocannabinoid System, and Türkiye’s New Legal Framework

Berk Sohtorik, Aliye Aras · 6 June 2026 · 25 min read

Kenevir Tarım A.Ş. · ANATABDER · Amasya University Hemp Application and Research Coordination Office

Summary

Hemp (Cannabis sativa L.) is one of the oldest cultivated plants in human history, used for thousands of years as food, fiber, medicine, and industrial raw material. In the 20th century, however, legal regulations and economic policies significantly restricted its agricultural and medicinal uses. This study reviews the botanical characteristics, evolutionary origins, historical uses, and phytotherapeutic importance of hemp in light of current scientific data. It also examines findings on the cultural and medicinal use of hemp in the historical process from Mesopotamia to Anatolia, and summarizes scientific developments on the discovery of the Endocannabinoid System and the effects of phytocannabinoids on human health. The study also reviews the re-evaluation of hemp in modern pharmacology and the legal regulations enacted in Türkiye in recent years. Drawing on the scientific literature and historical records together, the study argues that hemp is not merely an industrial plant but also a strategic plant with high medicinal, aromatic, and economic potential. In this respect, the study considers the historical continuity of hemp within Anatolia’s plant heritage and its renewed importance today from a holistic perspective.

Keywords: Cannabis sativa L., hemp, cannabinoid, heirloom seed, endocannabinoid system, Qunubu, Okinoshima, Tibetan Plateau, Malana Cream, legal regulation, phytocannabinoid

Introduction

Anatolia is one of the richest medicinal and aromatic plant regions in the world. Cannabis sativa L., one of the oldest agricultural and healing plants, which accompanied every stage of human social, economic, and cultural development and could meet the basic needs of societies, is an inseparable part of this unique biological heritage. Yet under the mounting pressure of legal, economic, and industrial forces in the 20th century, this ancient plant was pushed into obscurity for nearly a century and came close to being erased from our collective memory and from our soil. In line with the mission of ANATABDER, this review aims to make the historical position of hemp in Anatolia visible again and to contribute to preserving a plant memory that is at risk of being lost.

Although I come from a family with roots in seafaring, life took me on a very different course, and I found myself not at sea but on the land. Cannabis sativa L., the first plant I grew and witnessed through its entire life cycle from seed to harvest in the field, reinforced my admiration for the workings of nature. It also showed me that the most reliable way to keep heirloom seeds alive is to bring them back into contact with the soil. I supported this process with technical training, and I have been working in legal hemp cultivation in the field for many years.

Figure 1. Hemp Plant Sprouting from Soil. Photo: Author’s archive (Kastamonu, Türkiye, 2018)
Figure 1. Hemp Plant Sprouting from Soil. Photo: Author’s archive (Kastamonu, Türkiye, 2018)

What motivates me, both as a grower and as a researcher, is that hemp’s broad reach, from food to health and from construction to art, brings together experts from different sectors around a shared purpose. This collective knowledge moves hemp beyond being only an agricultural product and toward an interdisciplinary field of research.

Today in Türkiye we are witnessing hemp take its rightful place, from field to laboratory and from food to health, as the versatile companion of humanity it has been throughout its history. This new period is a unique opportunity for us as producers and researchers, and for all living beings who will encounter the potential hemp offers. Because the multilayered structure of hemp cannot be contained in a single text, this study is the first in a series of articles we are preparing for publication with ANATABDER.

Hemp (Cannabis sativa L.): Botanical Identity, Morphology, and Classification

Hemp (Cannabis sativa L.) is a comprehensive term that refers to the plant itself, the psychoactive and therapeutic compounds its trichomes produce, its fiber, shives, edible seed, and all related industrial, medicinal, and food uses. It was first scientifically described by Carl Linnaeus in Species Plantarum in 1753 and is an annual herbaceous plant (Linnaeus, 1753). In the current Angiosperm Phylogeny Group (APG) classification, it belongs to the family Cannabaceae, and the hop (Humulus) is its closest relative (APG IV, 2016; Sytsma et al., 2002).

Hemp is one of the most recognizable, most enigmatic, and therefore most controversial plants in the world. Most people who see hemp growing in a field for the first time are surprised by the plant’s size, appearance, and complex structure. It has gone through a long evolutionary process of adaptation to perform different functions. It is dioecious, meaning male and female flowers develop on separate plants, although we also encounter monoecious specimens that carry both sexes on a single plant.

Male flowers (staminate) hang in loose, highly branched clusters and produce pollen. Female flowers (pistillate) are tightly clustered among small leaves. Microscopic glands called trichomes, which cover their surfaces, produce the plant’s cannabinoids and terpenes. Known among growers as “resin factories,” these structures are the source of hemp’s medicinal and psychoactive compounds. These compounds are generally called phytocannabinoids, the best known of which are tetrahydrocannabinol (THC) and cannabidiol (CBD).

While female flowers produce these valuable molecules, male plants have historically been preferred for fine fiber, although fiber is obtained from the stalks of both sexes. The seeds contain omega-3 and omega-6 fatty acids in an ideal ratio and are among the most nutritious plant-based seeds, with high-quality protein content (Callaway, 2004).

For a long time it was debated whether sativa, indica, and ruderalis were separate species or subforms of a single species. Based on chemical content, hemp has been classified under a single species, Cannabis sativa L. (Small & Cronquist, 1976). Recent genomic findings show that the distinction between sativa and indica rests on terpene profiles, which supports a classification model that uses multiple chemotypes centered on cannabinoids and terpenes (Watts et al., 2021).

Hemp History, Evolutionary Origins, and the Process of Prohibition

Cannabis sativa L. resembles no other agricultural crop, and its journey through human history is anything but uniform. Reading this history accurately requires testing popular narratives against archaeobotanical and genomic data. Analytical technologies developed in recent years continue to produce new findings in this field.

Figure 2. Macro Photograph of Trichomes on the Hemp Plant. Photo: Nick Cash, Zoom Gardens (2026)
Figure 2. Macro Photograph of Trichomes on the Hemp Plant. Photo: Nick Cash, Zoom Gardens (2026)

Beyond industrial fiber and nutritious seed production, the regulatory effects that the secondary metabolites (cannabinoids and terpenes) secreted by hemp’s female flowers have on the human mind and body played a central role in the pharmacopeias of ancient civilizations. Humans understood the plant’s morphological distinctions through long observation and experience. They used its sturdy fibrous stalks for rope and textiles and its resinous female flowers for health and ritual. Yet centuries of this human-nature harmony gave way to a global prohibition era shaped by economic and political concerns.

Origin and Domestication

By synthesizing 155 fossil pollen studies conducted across Asia, researchers have mapped the evolutionary origin of hemp. Hemp and its closest relative, the hop (Humulus), are estimated to have diverged approximately 27.8 million years ago on the northeastern Tibetan Plateau, around Qinghai Lake. The oldest physical pollen traces of the plant were found in rock layers in China’s Ningxia region, dating to 19.6 million years ago (McPartland et al., 2019).

The start of the plant’s agricultural relationship with humans was clarified by analyzing the complete genome sequences of 110 accessions from around the world. Genomic data indicate that hemp was domesticated through a single event in early Neolithic East Asia, approximately 12,000 years ago (c. 10,000 BCE) (Ren et al., 2021). All modern hemp varieties descend from an ancestral gene pool, represented today by wild plants still found in nature.

Consistent with this genomic evidence, the oldest physical hemp seed samples dated by radiocarbon come from the Okinoshima finds in Japan (c. 8280–7660 BCE) (Kobayashi et al., 2008). Morphometric analyses showed that these seeds lack the “caruncle” structure found in wild hemp forms. The absence of the caruncle indicates that the plant had lost its natural seed-dispersal mechanism and points to a domesticated form selected by human hands (Dal Martello et al., 2024). The same caruncle absence is seen in Cannabis seeds from the Torihama shell mound in Japan, dated to the Jomon period (c. 5000 BCE). These findings fundamentally update the “Central Asian origin” hypothesis, which was accepted as the botanical knowledge of its time and held its validity for about a century (Vavilov, 1926). Central Asia is less the origin of the plant than the largest secondary center of diversity from which it spread across the world, and a historical bridge.

Earliest Industrial Uses

Some of the earliest known traces of industrial hemp use were identified through stratigraphic analyses at the Torihama shell mound in Japan (c. 5000 BCE) and in fiber and rope impressions on ceramics from the Banpo village of the Yangshao culture in China (c. 4115–3535 BCE) (Crawford, 2011). Remains from Taixi village in the Shang period (c. 14th century BCE) were long accepted in the archaeological literature as the oldest example of pure hemp cloth (Li, 1974). However, the fiber analysis of these finds relies on methods from the 1970s and needs to be re-verified using modern techniques such as Scanning Electron Microscopy (SEM) or Py-GC/MS (Pyrolysis Gas Chromatography-Mass Spectrometry). In historical samples, hemp, flax, nettle, and bast fibers are often confused with one another because of their morphological similarity, particularly in degraded archaeological finds.

A similar identification problem appears in the archaeobotanical data from Anatolia. Textile fragments found at Çatalhöyük (6700–6500 BCE) were long identified as flax in the academic literature, while popular accounts sometimes confused them with hemp (Helbæk, 1963; Burnham, 1965). A 2021 SEM analysis showed that the fibers were produced not from flax or hemp but from the inner bark (bast) fiber of local oak trees (Rast-Eicher et al., 2021).

One of the oldest verified pieces of evidence for the textile use of hemp was recently brought to light in Anatolia. Dr. Çiğdem Maner and colleagues examined two burned Bronze Age textile fragments found during the 2016–2018 excavations at Beycesultan Höyük (Denizli-Çivril) using chromatographic and microscopic methods. The fragment, dyed with woad and produced with the single-needle technique (nålbinding), has been dated to the Middle Bronze Age (1915–1745 BCE) and was identified as made from hemp fiber (Maner et al., 2025). This finding is much older than the samples from Taixi village (c. 14th century BCE), and it has entered the archaeological literature as one of the oldest hemp textile finds in Anatolia verified by modern methods.

Medical Hemp and the Pharmacopeia

The earliest written records of the medical use of hemp appear in Mesopotamia. The Library of Ashurbanipal (7th century BCE), a vast archive holding more than 30,000 clay tablets, is a remarkable repository. The plant appears in Akkadian as “azallû,” and the Latin word “Cannabis” is thought to derive from the term “Qunubu” found on the same tablets. Modern analyses of the tablets confirm that hemp was used for depression, in arthritic poultices, and for the treatment of kidney stones (Thompson, 1923; Scurlock & Andersen, 2005).

In Ancient Egyptian hieroglyphs, hemp appears as “shemshemet.” The Ramesseum III Papyrus (c. 1700 BCE) recommends the plant for eye diseases, while the 20-meter Ebers Papyrus (1550 BCE) documents its use to relieve uterine pain (Russo, 2007).

Figure 3. Fragment of a Neo-Assyrian cuneiform plant dictionary from the Library of Ashurbanipal (7th century BCE) containing the entry for hemp (azallû) (Museum No: K.4345). Photo: British Museum Archive
Figure 3. Fragment of a Neo-Assyrian cuneiform plant dictionary from the Library of Ashurbanipal (7th century BCE) containing the entry for hemp (azallû) (Museum No: K.4345). Photo: British Museum Archive

In the Indian subcontinent, hemp is both a medicine and a sacred ritual tool. The Atharva Veda (c. 1500–1000 BCE) names hemp as one of the five sacred plants of the earth (Griffith, 1895–1896). Ayurvedic medicine used hemp in three forms: bhang (leaf), ganja (flower), and charas (resin). The texts document 191 formulations for 29 diseases (Ram et al., 2018). The best-known contemporary representative of this traditional charas culture is “Malana Cream,” a resin produced by hand-rubbing in the Malana valley of the Himalayas. As I observed during my visits to the region, the local community’s uninterrupted continuation of this traditional production is a striking example of how a landrace has been preserved through a human-plant partnership.

In China, medical use is traced to the legendary Emperor Shen Nung (traditionally dated to the 3rd millennium BCE), but the written compilation of this knowledge in the Pen Ts’ao Ching coincides with the Han dynasty (1st century CE) (Li, 1974). Phytochemical and genetic analyses of a 789-gram pile of hemp placed in the grave of a shaman at the Yanghai cemetery (c. 700 BCE) found THC in the samples. They indicated that the material was selected for psychoactive and ritual use rather than for fiber or food (Jiang et al., 2006; Russo et al., 2008).

The Scythian hemp steam bath ritual described by Herodotus (c. 440 BCE) has been archaeologically confirmed at the Pazyryk kurgans in the Altai Mountains (5th to 3rd centuries BCE) (Herodotus, 1920).

The figure who carried this accumulated knowledge into Western medicine was the physician Pedanius Dioscorides, born in Anazarbus (present-day Anavarza, Adana-Kozan). In his De Materia Medica, written in the 1st century CE, he divided hemp into parts (seed, fresh plant juice, and root) and assigned a separate indication to each (Dioscorides, 2005). Pliny recorded that hemp juice expelled worms and insects that had entered the ear, but that this happened with a headache (sed cum dolore capitis) (Pliny, 1950). Galen assessed the pharmacological profile of hemp within the humoral framework in De alimentorum facultatibus (Galenus, 2003; Brunner, 1977). This systematized pharmacopeial tradition remained the core reference of European medicine for roughly 1,500 years.

During the Islamic Golden Age, Ibn Sina (980–1037) assessed hemp within Galen’s humoral grading system in his El-Kanun fi’t-Tıbb (c. 1025).

In the traditional medical literature, the plant’s seeds (şahdanec) were classified as “hot and dry,” while the leaf and resin parts (qunnab/hashish), which produce the main medicinal and psychoactive effects, were generally considered “cold and dry” in temperament. Excessive use was said to disturb the temperament and lead to melancholy (Ibn Sina, 1999). The Canon remained a textbook in European medical faculties until the late 17th century. This body of knowledge, stretching from Ancient Greece to the Islamic Golden Age, was carried into modern Western medicine in the 19th century. The United States Pharmacopeia listed hemp as an official drug from 1850 to 1942 (United States Pharmacopeial Convention, 1851, 1942). Pharmaceutical companies such as Parke-Davis and Eli Lilly produced hemp tinctures (Musto, 1999).

Exclusion from Medical Use and the Prohibition Process

The medical use of hemp entered a process of systematic exclusion with the radical standardization movement that began in medical education in the early 20th century. The greatest turning point in this change was the 1910 Flexner Report on Medical Education (Flexner, 1910). In this new period, when a single scientific standard was imposed on medical education, schools that did not meet the report’s criteria were closed. Holistic and traditional approaches to healing, such as phytotherapy, naturopathy, homeopathy, and physiomedicalism (botanical medicine), were effectively marginalized by being declared “unscientific.”

At the time, most of the official drugs in the US Pharmacopeia were still made from crude plant extracts. With this rupture, however, the pharmaceutical industry shifted to a reductionist model focused on a single molecule and a single disease target. Isolated, standardizable, and patentable chemical compounds came to be regarded as the only valid treatments, while botanical preparations containing hundreds of active components, such as hemp, were rapidly removed from the modern pharmacopeia.

Excluded from the academic and pharmaceutical world, hemp’s industrial versatility also created a conflict of interest with sectors such as textiles, paper, energy, and petrochemicals. These sectors were expanding rapidly and were dominated by large capital groups in that period. As a plant that alone threatened these sectors, hemp became the target of aggressive economic warfare and systematic propaganda.

The manipulative and sensationalist campaigns led by Harry Anslinger, head of the Federal Bureau of Narcotics (FBN), with the support of media magnate William Randolph Hearst, including the “Reefer Madness” campaign, aimed to create fear and panic about hemp among the public. The 1937 US Marihuana Tax Act, which sought to economically strangle the plant rather than ban it outright, passed through Congress in a very short session (Bonnie & Whitebread, 1974). Although the American Medical Association (AMA) openly protested that the law lacked a scientific basis, its objection was ignored.

That the United States, despite all of this prohibition lobbying, called on its own growers during World War II to grow hemp for military equipment through the “Hemp for Victory” campaign (United States Department of Agriculture, 1942) is the clearest evidence of this economic double standard and pragmatic approach.

The use of hemp by many countries as an independent resource for fiber, food, medicine, energy, and agricultural inputs, within national agricultural strategies, threatened the long-term market dominance of the international pharmaceutical, paper, petrochemical, and alternative fiber industries. Anslinger gained considerable international influence as the chief US representative to the UN Commission on Narcotic Drugs and personally shaped the 1961 UN Single Convention. Hemp was placed in the same category as the most dangerous drugs with no medical value, such as heroin. Scientific research was choked by heavy bureaucratic obstacles for years and pushed out of mainstream academia (United Nations, 1961).

In the 1930s and 1970s, the addition of the seed to the scope of intellectual property rights completed this pressure regime with agricultural monopolization (Plant Patent Act, 1930; Plant Variety Protection Act, 1970). The combination of prohibitions and patents kept hemp away from both the soil and scientific research for more than half a century. It also pushed the traditional grower networks that produced with heirloom seed outside the global agricultural market.

The Scientific Revolution and the Endocannabinoid System

Despite thousands of years of human use, the way cannabis acts in the body (its therapeutic mechanism) had not yet been fully explained. Political and industrial prohibitions erased the plant's agricultural presence, but they could not stop researchers' curiosity. Interestingly, the answers began to arrive during the period of the most intense prohibitions. This sequence of discoveries, which began with the isolation of the plant's active components, ended with the mapping of the largest homeostatic balance network the human body has, one that had been unknown until then: the Endocannabinoid System (ECS).

Phytocannabinoids and Terpenes: The Chemistry of the Plant

The pharmacological power of cannabis is concentrated in the secretory cavities of glandular trichomes. These microscopic structures synthesize and store two main groups of compounds that together define the plant's chemistry: phytocannabinoids and terpenes.

To date, more than one hundred different phytocannabinoids have been identified. The great majority are produced in acidic form (e.g., THCA and CBDA). Although the acidic forms have their own properties, thermal decarboxylation (the application of heat) is required for cannabis to display its well-known core pharmacological effects. The therapeutic profiles of raw plant material and heated plant material differ considerably (Kaminski et al., 2024). In addition to THC and CBD, the major cannabinoids that have been studied most, minor cannabinoids such as cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV) are at the center of scientific interest because of their distinctive therapeutic potential.

Terpenes are secondary metabolites also found in many species of Anatolia's medicinal and aromatic flora, such as thyme, sage, rosemary, black horehound, and bay laurel. Terpenes synthesized together with phytocannabinoids are thought to do more than determine the plant's aroma profile. By interacting with these compounds, they are also believed to contribute to the therapeutic effect. This approach, called the entourage effect, treats cannabis as a working whole rather than a sum of separate components (Russo, 2011).

Chronology of Discoveries: From THC to the Endocannabinoid System

The first step of the scientific revolution was taken in 1964 by Dr. Raphael Mechoulam and his team, who are regarded as the founders of modern cannabinoid science. Working with samples obtained from seized smuggled Lebanese hashish, they isolated the main psychoactive component of cannabis, Delta-9-Tetrahydrocannabinol (Δ⁹-THC), and defined its molecular structure (Gaoni & Mechoulam, 1964). In the same period, the structure of the non-psychoactive cannabidiol (CBD) was also elucidated, revealing the chemical profile of the plant. This discovery moved cannabis from a "mysterious plant" to a medical resource whose dose and effect can be measured.

The structure of THC had been solved, but why and how the plant acted in the body was still unknown. To understand the source of this compatibility, one has to know that the word "cannabinoid" covers two different worlds. Molecules the plant naturally produces are called phytocannabinoids (phyto = plant), while molecules our own bodies produce are called endocannabinoids (endo = internal). The discovery of the system that connects these two groups of molecules is as compelling a story as the plant itself.

– Receptors (Locks): CB1 and CB2 Understanding the effects of cannabis in the body became possible by identifying the cellular gates to which the plant's active molecules bind. In 1988, the CB1 receptor was discovered: a specific protein structure to which THC binds in the brain (Devane et al., 1988). CB1 is found in the brain at higher density than any other G-protein-coupled receptor, with high concentrations in the hippocampus, amygdala, basal ganglia, and cerebellum. It plays a role in regulating pain perception, memory, appetite, sense of well-being, and motor control. This discovery put on a scientific footing why human physiology is so responsive to cannabis.

In 1993, the CB2 receptor was described. It is found mainly in the peripheral nervous system and in immune cells (spleen, tonsils, leukocytes) (Munro et al., 1993). Unlike CB1, CB2 activation modulates inflammation and pain responses without producing any psychoactive effect.

– Endocannabinoids (Keys): Anandamide and 2-AG If the body has receptors (locks), it must also produce its own "internal keys" to open them. Anandamide (1992), the first endocannabinoid, was isolated and described by Raphael Mechoulam and his team. It takes its name from the Sanskrit word ānanda, meaning "bliss, joy," which reflects the molecule's role in feelings of well-being and mood regulation (Devane et al., 1992).

2-Arachidonoylglycerol (2-AG, 1995) was discovered simultaneously by two independent teams (Mechoulam et al., 1995; Sugiura et al., 1995). Anandamide performs more selective, fine-tuning functions, while 2-AG is the main carrier of cannabinoid activity in the brain. It acts as a full agonist at both CB1 and CB2 receptors.

In science, these endocannabinoids are called "endogenous ligands" (internal binding molecules), and their discovery revealed a basic fact: the phytocannabinoids produced by the plant acted by binding to the same receptors (CB1 and CB2) as the body's own endocannabinoids. In other words, the cannabis plant was speaking a language our bodies already knew. Anandamide and THC are two different keys that open the same lock (the CB1 receptor): one produced by the body itself, the other offered by the plant.

– Metabolic Enzymes: FAAH and MAGL Unlike classical neurotransmitters, endocannabinoids are synthesized when needed and are not stored in the body. For this reason, the ECS has enzymes that rapidly break down endocannabinoids once signaling is complete. FAAH (fatty acid amide hydrolase) breaks down anandamide, and MAGL (monoacylglycerol lipase) breaks down 2-AG, ending the signal.

The most important difference between them is durability. Anandamide is broken down by FAAH within seconds, whereas THC resists these enzymes and can remain in the body for hours. This difference explains why the plant is such a powerful therapeutic agent: phytocannabinoids work like a "long-acting version" of the body's own system.

– Retrograde Signaling The most revolutionary feature that distinguishes the ECS from other signaling systems is the direction of transmission. In 2001, Wilson and Nicoll discovered that endocannabinoids act as retrograde (backward-traveling) signal carriers (Wilson & Nicoll, 2001). In classical nerve transmission, information flows in one direction: from the sending cell (presynaptic) to the receiving cell (postsynaptic).

If the sending cell is overstimulated, the receiving cell can be damaged. This is where the ECS comes into play. The overstimulated receiving cell synthesizes endocannabinoids (anandamide or 2-AG) on demand from fatty acids in its membrane. These molecules spread backward across the synaptic cleft, bind to the CB1 receptor of the sending cell, close calcium channels, and slow the release of neurotransmitters.

Dr. Rachel Knox summarizes this mechanism in one of her talks as follows: “The ECS is like a control mechanism that balances the noise of the nervous system. If your neighbor (the sending cell) turns the music up too loud, you (the receiving cell) knock on the door and ask, ‘Could you turn the music down a little?’ Endocannabinoids are precisely that ‘adjust the volume’ message the receiving cell sends back to the sender. Plant-derived cannabinoids do exactly this job of knocking on that door, and that is how they maintain balance in the body” (Knox, 2019).

The Endocannabinoid System

When all of these cellular and molecular discoveries are put together, the picture is this: the Endocannabinoid System (ECS) is a broad signaling and balancing network that exists independently of the cannabis plant and works with molecules the body itself produces. Its components can be traced back about 600 million years, and the system has been identified across a very wide range of the biological world, including mammals (McPartland et al., 2006).

The core function of the ECS is homeostasis, that is, maintaining internal balance. Processes that seem very different from one another, such as pain perception, appetite, sleep, sense of well-being, immune response, memory, reproduction, bone health, and body temperature, are all balanced by this single system. The phytocannabinoids synthesized by cannabis are the most powerful molecular partners of this evolutionary communication network found in nature.

Healthy functioning of the ECS is directly supported by basic daily practices such as nutrition, sleep, physical activity, and stress management. Disruption of this balance has been associated with conditions such as chronic pain, inflammation, sleep disorders, and metabolic diseases. At a time when modern life makes this balance increasingly difficult to maintain, the therapeutic importance of phytocannabinoids that can modulate the ECS is becoming clearer across a broad range of living organisms, including humans and other mammals. However, this effect does not appear in the same way in everyone;

each individual's genetic and metabolic makeup can change the response to the same compound. For this reason, the effect of cannabis should be considered a person-specific interaction rather than a fixed prescription, and the pharmacogenetic approach, which examines individual differences, is gaining importance as well. Türkiye has joined the countries taking part in this scientific awakening.

Türkiye’s New Cannabis Era and Its Legal Framework

The legal framework rests essentially on Law No. 2313 on the Control of Narcotic Drugs (Uyuşturucu Maddelerin Murakabesi Hakkında Kanun), dated 12 June 1933. It never banned cannabis outright. By bringing production under state control, however, it defined the plant for decades only as an industrial raw material focused on fiber and seed. This restricted definition left the plant's therapeutic value and modern industrial applications in a legal blind spot.

Under pressure and an embargo threat from the Nixon administration in the United States, the Nihat Erim government, formed after the 12 March Memorandum (Muhtıra), halted opium poppy cultivation by a 1971 decree. An important distinction should be stressed here: this ban was not aimed directly at cannabis. However, the political atmosphere created by the poppy crisis, the rise of synthetic fibers, and the "narcotic" label attached to both plants effectively collapsed cannabis cultivation in Türkiye. Production areas that exceeded thousands of hectares in 1961 shrank to a level where only symbolic production of a few hectares took place in 2013 (Clarke, 2023; FAOSTAT, 2020).

For licensed cannabis growers in Türkiye, the years when production was limited to fiber, shives, and seed were a period in which the most valuable parts of the plant were necessarily wasted. During fiber and seed harvests, the legal framework of the time did not allow medical use, so the flower parts of the plant had to be burned and destroyed in the field as required by regulation (Kenevir Yetiştiriciliği ve Kontrolü Hakkında Yönetmelik, 2016).

Finally, recent legal regulations have brought this mandatory "destruction" period to an end. Cannabis flower is no longer an element to be burned and has become a legal component of products derived from cannabis. Today, cannabis cultivation for THC and CBD purposes is carried out under the supervision of the Toprak Mahsulleri Ofisi (Turkish Grain Board), within a presidential quota of 120,000 plants per year, determined according to the country's supply and demand (Cumhurbaşkanlığı Kota Kararı, 2024). The value chain is shared between two ministries. Cultivation and harvesting remain under the authority of the Tarım ve Orman Bakanlığı (Ministry of Agriculture and Forestry), while processing, licensing, and sale of products are assigned to the Sağlık Bakanlığı (Ministry of Health). Cannabis-based products are divided into four main categories: medical, health, supportive, and personal care products. All of these products may be sold only through pharmacies. Because therapeutic response varies from person to person, bringing cannabis into use step by step, as a prescribed product, makes the process both safe and consistent. This structural transformation has opened the way for the plant, with its entire morphology, to come under medical regulation and to be evaluated to its full potential (7442 sayılı Kanun, 2023; 7557 sayılı Kanun, 2025; Kenevir Yetiştiriciliği ve Kontrolüne Dair Yönetmelik, 2026; Kenevirden Elde Edilen Ürünlere Dair Yönetmelik, 2026).

Figure 4. Seed and Stalk Harvest in Open-Field Cannabis Plots in Türkiye. Photo: Author's archive (Sinop, Türkiye, 2021)
Figure 4. Seed and Stalk Harvest in Open-Field Cannabis Plots in Türkiye. Photo: Author's archive (Sinop, Türkiye, 2021)

Alongside industrial cultivation, a new production model is being added in controlled facilities. It is based on science and high added value, and it is aimed at the country's economy and health. Medical cannabis production, however, is still a young and rapidly developing sector in our country. Field practices, the safe access of patients in the domestic market to these products, and the gradual maturation of the legal infrastructure, in line with the country's goals in the global market, are expected. This process could bring Türkiye's production potential to a strategic and competitive position, both in the domestic health system and internationally.

As a stakeholder in this national transformation, we have long focused on both the theoretical research and the field practice of cannabis. With the current medical cannabis cultivation permits issued under Türkiye’s new legal framework, our work on genetic stabilization, cultivation in line with standards, and correct extraction methods aims to integrate the plant safely into modern medicine. Turning the accumulated academic literature into concrete production models at our controlled facilities is the foundation of the sectoral vision we hold.

Figure 5. High-Technology Production Facility of Linsboer, a Licensed Dutch Cannabis Producer. Photo: Author's archive (Lelystad, Netherlands, 2026)
Figure 5. High-Technology Production Facility of Linsboer, a Licensed Dutch Cannabis Producer. Photo: Author's archive (Lelystad, Netherlands, 2026)

Afterword

Following a long period of prohibition, the new regulations that have begun in Türkiye place cannabis on a legal footing and prepare the ground for evidence-based use of the plant's medical potential. The shared aim in this field is for the highest-quality products to reach patients in need of healing safely.

Although the medical dimension has been emphasized in this study, cannabis is a holistic plant that cannot be reduced to a single sector or to isolated active components. Its uses in health, cosmetics, food, textiles, construction, and agriculture offer an opportunity to bring together traditional Anatolian plant knowledge and the methods of modern science. This encounter, by repairing the connections that pharmaceutical reductionism has severed, will help us understand the plant's contribution to human health and ecology more fully.

As the legal and technical infrastructure matures, cultivation may one day return to open fields, sunlight, and soil, and processing may continue to international standards. Such a development is promising for ecosystem and public health. Witnessing cannabis reconnect with this geography, which is home to a rich diversity of medicinal and aromatic plants, and with our culture of healing, is the most exciting period of our professional lives as growers, producers, and researchers. The bond between people and plants being rebuilt here is a shared gain for everyone who cares about plants.

Acknowledgments

I thank all our fellow travelers who put their labor and hearts into this story, all friends who take plants as their guide, our respected teachers Dilek Himam and Nazım Tanrıkulu, and the ANATABDER family.

References

  • 2313 sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun. (1933, 24 Haziran). Resmî Gazete (Sayı: 2435).
  • 7442 sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanunda Değişiklik Yapılmasına Dair Kanun. (2023, 5 Nisan). Resmî Gazete (Sayı: 32154).
  • 7557 sayılı Sağlıkla İlgili Bazı Kanunlarda ve 663 Sayılı Kanun Hükmünde Kararnamede Değişiklik Yapılmasına Dair Kanun. (2025, 24 Temmuz). Resmî Gazete (Sayı: 32965).
  • Angiosperm Phylogeny Group (APG IV). (2016). An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG IV. Botanical Journal of the Linnean Society, 181(1), 1–20.
  • Bonnie, R. J., & Whitebread, C. H. (1974). The Marihuana conviction: A history of marihuana prohibition in the United States. University Press of Virginia.
  • Brunner, T. F. (1977). Marijuana in ancient Greece and Rome? The literary evidence. Journal of Psychedelic Drugs, 9(3), 221–225.
  • Burnham, H. B. (1965). Çatal Hüyük – The textiles and twined fabrics. Anatolian Studies, 15, 169–174.
  • Callaway, J. C. (2004). Hempseed as a nutritional resource: An overview. Euphytica, 140(1–2), 65–72.
  • Clarke, R. C. (2023). Anatolian hemp (Cannabis sativa L.) cultivation, processing, and production: History and recent observations. Agrociencia Uruguay, 27, e1166.
  • Crawford, G. W. (2011). Advances in understanding early agriculture in Japan. Current Anthropology, 52(S4), 331–345.
  • Cumhurbaşkanlığı Kota Kararı. (2024, 30 Ekim). Resmî Gazete (Sayı: 32707).
  • Dal Martello, R., vd. (2024). Morphometric approaches to cannabis evolution and differentiation from archaeological sites. Vegetation History and Archaeobotany, 33(4), 503–518.
  • Devane, W. A., vd. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34(5), 605–613.
  • Devane, W. A., Hanuš, L., vd. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.
  • Dioscorides, P. (2005). De Materia Medica (L. Y. Beck, Çev.). Olms-Weidmann.
  • FAOSTAT. (2020). Hemp production data Turkey. FAO.
  • Flexner, A. (1910). Medical education in the United States and Canada. Carnegie Foundation.
  • Galenus. (2003). On the properties of foodstuffs (O. Powell, Çev.). Cambridge University Press.
  • Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society, 86(8), 1646–1647.
  • Griffith, R. T. H. (Çev.). (1895–1896). The Hymns of the Atharva Veda (Kitap 11, İlahi 6, Ayet 15). E. J. Lazarus.
  • Helbæk, H. (1963). Textiles from Çatal Hüyük. Archaeology, 16(1), 39–46.
  • Herodotus. (1920). Tarihler (Historiai) (Kitap IV, 73–75, A. D. Godley, Çev.). Harvard University Press.
  • İbn Sina (Avicenna). (1999). El-Kanun fi’t-Tıbb (The Canon of Medicine) (L. Bakhtiar, Uyar.). KAZI Publications.
  • Jiang, H.-E., vd. (2006). A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai tombs, Xinjiang, China. Journal of Ethnopharmacology, 108(3), 414–422.
  • Kaminski, K. P., vd. (2024). Opportunities, challenges, and scientific progress in hemp crops. Molecules, 29(10), 2297.
  • Kenevir Yetiştiriciliği ve Kontrolü Hakkında Yönetmelik. (2016, 29 Eylül). Resmî Gazete (Sayı: 29842). Kenevir Yetiştiriciliği ve Kontrolüne Dair Yönetmelik. (2026, 31 Ocak). Resmî Gazete (Sayı: 33154).
  • Kenevirden Elde Edilen Ürünlere Dair Yönetmelik. (2026, 31 Ocak). Resmî Gazete (Sayı: 33154).
  • Knox, R. (2019). The endocannabinoid system and your health. TEDxPortland.
  • Kobayashi, M., Momohara, A., Okazaki, K., vd. (2008). Fossil hemp fruits in the earliest Jomon period from the Okinoshima site, Chiba Prefecture. Japanese Journal of Historical Botany, 16(1), 11–18.
  • Li, H.-L. (1974). An archaeological and historical account of cannabis in China. Economic Botany, 28(4), 437–448.
  • Linnaeus, C. (1753). Species Plantarum. Laurentii Salvii.
  • Maner, Ç., Abay, E., Karadağ, R., & Torgan Güzel, E. (2025). Untwisting Beycesultan Höyük: The earliest evidence for nålbinding and indigo-dyed textiles in Anatolia. Antiquity, 99(403), 118-134.
  • McPartland, J. M., vd. (2006). Evolutionary origins of the endocannabinoid system. Gene, 370, 64–74.
  • McPartland, J. M., Hegman, W., & Long, T. (2019). Cannabis in Asia: Its center of origin and early cultivation. Vegetation History and Archaeobotany, 28(6), 691–702.
  • Mechoulam, R., Ben-Shabat, S., vd. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.
  • Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61–65.
  • Musto, D. F. (1999). The American disease: Origins of narcotic control (3. baskı). Oxford University Press.
  • Plant Patent Act of 1930, 35 U.S.C. §§ 161–164 (1930).
  • Plant Variety Protection Act of 1970, 7 U.S.C. §§ 2321–2582 (1970).
  • Pliny (Gaius Plinius Secundus). (1950). Natural History (H. Rackham, Çev.). Harvard University Press.
  • Ram, G. S., Murthy, C. S., & Nanjundaiah, S. (2018). Vijaya (Cannabis sativa Linn.) and its therapeutic importance in Ayurveda: A review. Journal of Indian System of Medicine, 6(3), 157–163.
  • Rast-Eicher, A., Karg, S., & Bender Jørgensen, L. (2021). The use of local fibres for textiles at Neolithic Çatalhöyük. Antiquity, 95(383), 1129–1144.
  • Ren, G., vd. (2021). Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa. Science Advances, 7(29), eabg2286.
  • Russo, E. B. (2007). History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & Biodiversity, 4(8), 1614–1648.
  • Russo, E. B., Jiang, H. E., Li, X., vd. (2008). Phytochemical and genetic analyses of ancient cannabis from Central Asia. Journal of Experimental Botany, 59(15), 4171– 4182.
  • Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
  • Scurlock, J., & Andersen, B. R. (2005). Diagnoses in Assyrian and Babylonian medicine. University of Illinois Press.
  • Small, E., & Cronquist, A. (1976). A practical and natural taxonomy for cannabis. Taxon, 25(4), 405–435.
  • Sugiura, T., vd. (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215(1), 89–97.
  • Sytsma, K. J., vd. (2002). Urticalean rosids: Circumscription, rosid ancestry, and phylogenetics based on rbcL, trnL-F, and ndhF sequences. American Journal of Botany, 89(9), 1531–1546.
  • Thompson, R. C. (1923). Assyrian medical texts from the originals in the British Museum. Oxford University Press.
  • United Nations. (1961). Single Convention on Narcotic Drugs, 1961. UN.
  • United States Department of Agriculture. (1942). Hemp for Victory [Belgesel film]. USDA.
  • United States Pharmacopeial Convention. (1851). The Pharmacopoeia of the United States of America (3. baskı). Mack Printing.
  • United States Pharmacopeial Convention. (1942). The Pharmacopoeia of the United States of America (12. baskı).
  • Vavilov, N. I. (1926). Studies on the origin of cultivated plants. Institute of Applied Botany and Plant Breeding.
  • Watts, S., vd. (2021). Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants, 7, 1330–1334.
  • Wilson, R. I., & Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410(6828), 588–592.

This article was first published in ANATABDER's Anadolu’nun Bitki Mirası (Plant Heritage of Anatolia) publication: anatab.org